PRQR
ProQR Therapeutics BV
1.70$
+0.0%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 5,755.3% | 5.1% | 56.2% | – | 19.9% | 6,043.6% | 213.2% | – | 68.9% | 2.0% | – | 17.0% | |
| 100.0% | 94.9% | 43.8% | – | 80.1% | -5,943.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 83.0% | |
| 3,280.2% | 248.8% | 1,398.9% | – | 597.3% | 2,405.1% | 3,706.0% | 3,162.5% | 1,415.3% | 386.1% | 192.3% | 266.5% | |
| 2,078.9% | 72.7% | 415.3% | – | 253.8% | 666.7% | 1,329.9% | 1,301.0% | 518.9% | 249.2% | 72.3% | 98.6% | |
| 5,359.1% | 321.4% | 1,814.2% | – | 851.1% | 3,071.8% | 4,217.4% | 4,385.4% | 1,913.0% | 589.1% | 261.2% | 358.9% | |
| -5,259.1% | -287.1% | -1,734.1% | – | -734.5% | -2,971.8% | -4,117.4% | -4,285.4% | -1,813.0% | -489.1% | -161.2% | -275.9% | |
| 84.7% | 4.2% | 23.6% | – | 16.4% | 56.0% | 198.3% | 255.1% | 142.7% | 18.5% | 5.7% | 5.7% | |
| -3,874.4% | -221.5% | -1,713.5% | – | -750.6% | -2,928.8% | -4,518.0% | -4,545.5% | -1,783.8% | -427.0% | -147.9% | -265.1% | |
| -1,384.7% | -65.6% | -20.6% | – | 0.0% | 6.8% | 12.1% | 8.8% | 2.7% | -1.2% | -1.0% | 0.1% | |
| -3,874.4% | -221.5% | -1,713.5% | – | -746.7% | -2,935.6% | -4,525.3% | -4,549.8% | -1,792.5% | -431.7% | -146.9% | -265.2% | |
| -15,877.3% | -895.5% | -5,282.5% | – | -714.3% | -9,015.4% | -4,707.1% | -4,116.0% | -1,571.0% | -369.9% | -127.6% | -242.4% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.